MX348361B - Formulaciones resistentes al abuso. - Google Patents
Formulaciones resistentes al abuso.Info
- Publication number
- MX348361B MX348361B MX2012006829A MX2012006829A MX348361B MX 348361 B MX348361 B MX 348361B MX 2012006829 A MX2012006829 A MX 2012006829A MX 2012006829 A MX2012006829 A MX 2012006829A MX 348361 B MX348361 B MX 348361B
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- abuse
- hydromorphone
- resistant formulations
- sustained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta revelación se refiere a una forma farmacéutica oral de liberación sostenida para la administración de una vez al día que comprende una matriz que contiene un modificador de la viscosidad y gránulos revestidos que contienen hidromorfona. La forma farmacéutica puede tener un perfil de liberación de modo tal que 16 horas después de la administración, se libera menos de alrededor de 85 por ciento de la hidromorfona. Además, la forma farmacéutica puede tener resistencia al alcohol y/o a la trituración.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28751509P | 2009-12-17 | 2009-12-17 | |
PCT/US2010/060755 WO2011084593A2 (en) | 2009-12-17 | 2010-12-16 | Abuse-resistant formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012006829A MX2012006829A (es) | 2012-07-10 |
MX348361B true MX348361B (es) | 2017-06-07 |
Family
ID=43618139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012006829A MX348361B (es) | 2009-12-17 | 2010-12-16 | Formulaciones resistentes al abuso. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20120225122A1 (es) |
EP (1) | EP2512456A2 (es) |
JP (1) | JP5894717B2 (es) |
CN (1) | CN102665694A (es) |
AU (1) | AU2010339882B2 (es) |
CA (1) | CA2784407A1 (es) |
IL (1) | IL219961A (es) |
MX (1) | MX348361B (es) |
NZ (1) | NZ600640A (es) |
WO (1) | WO2011084593A2 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8784336B2 (en) | 2005-08-24 | 2014-07-22 | C. R. Bard, Inc. | Stylet apparatuses and methods of manufacture |
US8388546B2 (en) | 2006-10-23 | 2013-03-05 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US7794407B2 (en) | 2006-10-23 | 2010-09-14 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
US8781555B2 (en) | 2007-11-26 | 2014-07-15 | C. R. Bard, Inc. | System for placement of a catheter including a signal-generating stylet |
US9456766B2 (en) | 2007-11-26 | 2016-10-04 | C. R. Bard, Inc. | Apparatus for use with needle insertion guidance system |
US10449330B2 (en) | 2007-11-26 | 2019-10-22 | C. R. Bard, Inc. | Magnetic element-equipped needle assemblies |
US9649048B2 (en) | 2007-11-26 | 2017-05-16 | C. R. Bard, Inc. | Systems and methods for breaching a sterile field for intravascular placement of a catheter |
CN101925333B (zh) | 2007-11-26 | 2014-02-12 | C·R·巴德股份有限公司 | 用于脉管系统内的导管放置的集成系统 |
US10751509B2 (en) | 2007-11-26 | 2020-08-25 | C. R. Bard, Inc. | Iconic representations for guidance of an indwelling medical device |
US9521961B2 (en) | 2007-11-26 | 2016-12-20 | C. R. Bard, Inc. | Systems and methods for guiding a medical instrument |
US8849382B2 (en) | 2007-11-26 | 2014-09-30 | C. R. Bard, Inc. | Apparatus and display methods relating to intravascular placement of a catheter |
US10524691B2 (en) | 2007-11-26 | 2020-01-07 | C. R. Bard, Inc. | Needle assembly including an aligned magnetic element |
US8478382B2 (en) | 2008-02-11 | 2013-07-02 | C. R. Bard, Inc. | Systems and methods for positioning a catheter |
US9901714B2 (en) | 2008-08-22 | 2018-02-27 | C. R. Bard, Inc. | Catheter assembly including ECG sensor and magnetic assemblies |
US8437833B2 (en) | 2008-10-07 | 2013-05-07 | Bard Access Systems, Inc. | Percutaneous magnetic gastrostomy |
WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
US9532724B2 (en) | 2009-06-12 | 2017-01-03 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation using endovascular energy mapping |
CN102802514B (zh) | 2009-06-12 | 2015-12-02 | 巴德阿克塞斯系统股份有限公司 | 导管末端定位设备 |
AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
WO2011019760A2 (en) | 2009-08-10 | 2011-02-17 | Romedex International Srl | Devices and methods for endovascular electrography |
EP2517622A3 (en) | 2009-09-29 | 2013-04-24 | C. R. Bard, Inc. | Stylets for use with apparatus for intravascular placement of a catheter |
US11103213B2 (en) | 2009-10-08 | 2021-08-31 | C. R. Bard, Inc. | Spacers for use with an ultrasound probe |
CN102821679B (zh) | 2010-02-02 | 2016-04-27 | C·R·巴德股份有限公司 | 用于导管导航和末端定位的装置和方法 |
JP5980201B2 (ja) | 2010-05-28 | 2016-08-31 | シー・アール・バード・インコーポレーテッドC R Bard Incorporated | 針および医療用コンポーネントのための挿入誘導システム |
AU2011289513B2 (en) | 2010-08-09 | 2014-05-29 | C.R. Bard, Inc. | Support and cover structures for an ultrasound probe head |
KR101856267B1 (ko) | 2010-08-20 | 2018-05-09 | 씨. 알. 바드, 인크. | Ecg-기반 카테터 팁 배치의 재확인 |
WO2012058461A1 (en) | 2010-10-29 | 2012-05-03 | C.R.Bard, Inc. | Bioimpedance-assisted placement of a medical device |
KR102057430B1 (ko) | 2011-07-06 | 2019-12-18 | 씨. 알. 바드, 인크. | 삽입 유도 시스템을 위한 바늘 길이 결정 및 교정 |
USD699359S1 (en) | 2011-08-09 | 2014-02-11 | C. R. Bard, Inc. | Ultrasound probe head |
US9211107B2 (en) | 2011-11-07 | 2015-12-15 | C. R. Bard, Inc. | Ruggedized ultrasound hydrogel insert |
US20150086626A1 (en) * | 2012-04-17 | 2015-03-26 | Mylan, Inc | Stable dosage forms of skeletal muscle relaxants with extended release coating |
EP2861153A4 (en) | 2012-06-15 | 2016-10-19 | Bard Inc C R | APPARATUS AND METHODS FOR DETECTION OF A REMOVABLE CAP ON AN ULTRASONIC PROBE |
CN104768552A (zh) * | 2012-09-03 | 2015-07-08 | 第一三共株式会社 | 含有盐酸氢吗啡酮的口服持续释放药物组合物 |
CA2817728A1 (en) * | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CN105979868B (zh) | 2014-02-06 | 2020-03-10 | C·R·巴德股份有限公司 | 用于血管内装置的导向和放置的系统和方法 |
DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
US10973584B2 (en) | 2015-01-19 | 2021-04-13 | Bard Access Systems, Inc. | Device and method for vascular access |
WO2016210325A1 (en) | 2015-06-26 | 2016-12-29 | C.R. Bard, Inc. | Connector interface for ecg-based catheter positioning system |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US11000207B2 (en) | 2016-01-29 | 2021-05-11 | C. R. Bard, Inc. | Multiple coil system for tracking a medical device |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
CN112867443B (zh) | 2018-10-16 | 2024-04-26 | 巴德阿克塞斯系统股份有限公司 | 用于建立电连接的安全装备连接系统及其方法 |
AU2019386979B2 (en) | 2018-11-26 | 2023-03-16 | The Procter & Gamble Company | Solid pharmaceutical preparation containing lipoic acid and use thereof |
WO2021100728A1 (ja) | 2019-11-20 | 2021-05-27 | 塩野義製薬株式会社 | 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有固形製剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5223264A (en) | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
PE20001396A1 (es) * | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
AR049562A1 (es) * | 2004-07-01 | 2006-08-16 | Gruenenthal Gmbh | Formas farmaceuticas orales, con liberacion controlada de opioides, protegidas frente al abuso y procedimiento para su preparacion |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
PL2200593T3 (pl) * | 2007-09-13 | 2017-02-28 | Cima Labs Inc. | Preparat leku odporny na nadużywanie |
RS51313B (sr) * | 2007-11-09 | 2010-12-31 | Acino Pharma Ag.51311 | Retard tablete sa hidromorfonom |
EP2568977A1 (en) * | 2010-05-11 | 2013-03-20 | Cima Labs Inc. | Alcohol-resistant metoprolol-containing extended- release oral dosage forms |
-
2010
- 2010-12-16 NZ NZ600640A patent/NZ600640A/en not_active IP Right Cessation
- 2010-12-16 CA CA2784407A patent/CA2784407A1/en not_active Abandoned
- 2010-12-16 CN CN2010800576355A patent/CN102665694A/zh active Pending
- 2010-12-16 WO PCT/US2010/060755 patent/WO2011084593A2/en active Application Filing
- 2010-12-16 EP EP10801741A patent/EP2512456A2/en not_active Withdrawn
- 2010-12-16 JP JP2012544825A patent/JP5894717B2/ja not_active Expired - Fee Related
- 2010-12-16 AU AU2010339882A patent/AU2010339882B2/en not_active Ceased
- 2010-12-16 MX MX2012006829A patent/MX348361B/es active IP Right Grant
-
2012
- 2012-05-14 US US13/470,963 patent/US20120225122A1/en not_active Abandoned
- 2012-05-23 IL IL219961A patent/IL219961A/en not_active IP Right Cessation
-
2014
- 2014-06-05 US US14/296,572 patent/US9474721B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2010339882B2 (en) | 2016-10-27 |
MX2012006829A (es) | 2012-07-10 |
JP5894717B2 (ja) | 2016-03-30 |
CN102665694A (zh) | 2012-09-12 |
AU2010339882A1 (en) | 2012-07-05 |
IL219961A0 (en) | 2012-07-31 |
EP2512456A2 (en) | 2012-10-24 |
IL219961A (en) | 2017-06-29 |
US20140294953A1 (en) | 2014-10-02 |
JP2013514386A (ja) | 2013-04-25 |
WO2011084593A3 (en) | 2012-03-29 |
CA2784407A1 (en) | 2011-07-14 |
WO2011084593A2 (en) | 2011-07-14 |
US20120225122A1 (en) | 2012-09-06 |
NZ600640A (en) | 2014-11-28 |
US9474721B2 (en) | 2016-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ600640A (en) | Abuse-resistant formulations | |
MX347753B (es) | Formulaciones resistentes al abuso. | |
MY159630A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
CO6440564A2 (es) | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona | |
WO2008135527A3 (en) | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders | |
WO2007103200A3 (en) | Oral controlled release formulation for sedative and hypnotic agents | |
MX2012013021A (es) | Formulaciones resistentes a alcohol. | |
MX2007009162A (es) | Formas de dosis rsistente al alcohol. | |
NZ610701A (en) | Once daily formulation of lacosamide | |
MX2023008408A (es) | Composiciones antisentido, y metodos para obtener y usar las mismas. | |
MY156288A (en) | Pharmaceutical formulations containing dopamine receptor ligands. | |
MX343358B (es) | Tabletas de acetato de ulipristal. | |
TW200621317A (en) | Pharmaceutical composition | |
MY156332A (en) | Quinuclidine carbonate derivatives and medicinal composition thereof | |
MX2009004439A (es) | Composicion de ibuprofeno. | |
WO2011104652A3 (en) | Veterinary compositions | |
UA103179C2 (ru) | Фармацевтическая композиция, которая содержит эзетимиб | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
WO2012052169A3 (de) | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten | |
WO2008075320A3 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
MX2012013023A (es) | Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. | |
WO2009019662A3 (en) | Oral metaxalone compositions | |
GB2495563A (en) | Co-processed excipient compositions | |
WO2009069151A3 (en) | Controlled release composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |